Novartis Sues Aurobindo to Block Copies of Xiidra Dry-Eye Drug

Novartis said Aurobindo’s proposed generic version of a treatment for dry eye infringes 15 patents for Xiidra, which Novartis acquired in 2019 from Takeda for $3.4 billion.

• Novartis is seeking a court order blocking copies until the patents have expired, according to complaint filed Friday in federal court in Wilmington, Delaware
• Patents expire in November 2024 (5), March 2025, May 2026 (2), April 2029 (2), May 2029, October 2030 (2), November 2030 and July 2033: FDA Orange Book
• Xiidra is the only treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by ...